Skip to main content
banner image
No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
/content/aapm/journal/medphys/43/2/10.1118/1.4939223
1.
1.Z. Wang et al., “Charged particle radiation therapy for uveal melanoma: A systematic review and meta-analysis,” Int. J. Radiat. Oncol., Biol., Phys. 86, 1826 (2012).
http://dx.doi.org/10.1016/j.ijrobp.2012.08.026
2.
2.E. S. Gragoudas, “Proton beam irradiation of uveal melanomas: The first 30 years—The Weisenfeld lecture,” Invest. Opthalmol. Visual Sci. 47, 46664673 (2006).
http://dx.doi.org/10.1167/iovs.06-0659
3.
3.E. Egger et al., “Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma,” Int. J. Radiat. Oncol., Biol., Phys. 51, 138147 (2001).
http://dx.doi.org/10.1016/S0360-3016(01)01560-7
4.
4.M. Y. Chang and T. A. McCannel, “Local treatment failure after globe-conserving therapy for choroidal melanoma,” Br. J. Ophthalmol. 97, 804811 (2013).
http://dx.doi.org/10.1136/bjophthalmol-2012-302490
5.
5.K. K. Mishra et al., “Long-term results of the UCSF-LBNL randomized trial: Charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma,” Int. J. Radiat. Oncol., Biol., Phys. 92, 376383 (2015).
http://dx.doi.org/10.1016/j.ijrobp.2015.01.029
6.
6.A. Zytkovicz et al., “Peripheral dose in ocular treatments with CyberKnife and Gamma Knife radiosurgery compared to proton radiotherapy,” Phys. Med. Biol. 52, 59575971 (2007).
http://dx.doi.org/10.1088/0031-9155/52/19/016
7.
7.M. J. Sikuade et al., “Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma,” Eye 29, 11941198 (2015).
http://dx.doi.org/10.1038/eye.2015.109
8.
8.A. M. Allen et al., “An evidence based review of proton beam therapy: The report of ASTRO’s emerging technology committee,” Radiother. Oncol. 103, 811 (2012).
http://dx.doi.org/10.1016/j.radonc.2012.02.001
9.
9.The American Brachytherapy Society–Ophthalmic Oncology Task Force (ABS-OOTF), “The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma,” Brachytherapy 13, 114 (2014).
http://dx.doi.org/10.1016/j.brachy.2013.11.008
10.
10.A. Peeters, J. P. Grutters, M. Pijls-Johannesma, S. Reimoser, D. De Ruysscher, J. L. Severens, M. A. Joore, and P. Lambin, “How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons,” Radiother. Oncol. 95, 4553 (2010).
http://dx.doi.org/10.1016/j.radonc.2009.12.002
11.
11.J. L. Hungerford, A. J. Foss, I. Whelahan, R. D. Errington, A. Kacperek, and J. Kongerud, “Side effects of photon and proton radiotherapy for ocular melanoma,” Front. Radiat. Ther. Oncol. 30, 287293 (1997).
http://dx.doi.org/10.1159/000425715
12.
12.S. T. Chiu-Tsao, M. A. Astrahan, P. T. Finger, D. S. Followill, A. S. Meigooni, C. S. Melhus, F. Mourtada, M. E. Napolitano, R. Nath, M. J. Rivard, D. W. O. Rogers, and R. M. Thomson, “Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS,” Med. Phys. 39, 61616184 (2012).
http://dx.doi.org/10.1118/1.4749933
13.
13.P. K. Lommatzsch, C. Werschnik, and E. Schuster, “Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma,” Graefe’s Arch. Clin. Exp. Ophthalmol. 238, 129137 (2000).
http://dx.doi.org/10.1007/PL00007880
14.
14.Collaborative Ocular Melanoma Study Group, “Design and methods of a clinical trial for a rare condition: The Collaborative Ocular Melanoma Study: COMS Report No. 3,” Controlled Clin. Trials 14, 362391 (1993).
http://dx.doi.org/10.1016/0197-2456(93)90052-F
15.
15.Collaborative Ocular Melanoma Study Group, “The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS Report No. 28,” Arch. Ophthalmol. 124, 16841693 (2006).
http://dx.doi.org/10.1001/archopht.124.12.1684
16.
16.S. Nag et al., “The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas,” Int. J. Radiat. Oncol., Biol., Phys. 56, 544555 (2003).
http://dx.doi.org/10.1016/S0360-3016(03)00006-3
17.
17.J. P. Moriarty et al., “Cost-effectiveness of proton beam therapy for intraocular melanoma,” PLoS One 10(5), e0127814 (2015).
http://dx.doi.org/10.1371/journal.pone.0127814
18.
18.K. K. Mishra et al., “Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: A detailed analysis of tumor and dose-volume parameters,” Int. J. Radiat. Oncol., Biol., Phys. 87, 330336 (2013).
http://dx.doi.org/10.1016/j.ijrobp.2013.05.051
http://aip.metastore.ingenta.com/content/aapm/journal/medphys/43/2/10.1118/1.4939223
Loading
/content/aapm/journal/medphys/43/2/10.1118/1.4939223
Loading

Data & Media loading...

Loading

Article metrics loading...

/content/aapm/journal/medphys/43/2/10.1118/1.4939223
2016-01-13
2016-09-28

Abstract

There is no abstract available for this article.

Loading

Full text loading...

/deliver/fulltext/aapm/journal/medphys/43/2/1.4939223.html;jsessionid=-A39lWe4sxR83d5MMboJfO5C.x-aip-live-06?itemId=/content/aapm/journal/medphys/43/2/10.1118/1.4939223&mimeType=html&fmt=ahah&containerItemId=content/aapm/journal/medphys
true
true

Access Key

  • FFree Content
  • OAOpen Access Content
  • SSubscribed Content
  • TFree Trial Content
752b84549af89a08dbdd7fdb8b9568b5 journal.articlezxybnytfddd
/content/realmedia?fmt=ahah&adPositionList=
&advertTargetUrl=//oascentral.aip.org/RealMedia/ads/&sitePageValue=online.medphys.org/43/2/10.1118/1.4939223&pageURL=http://scitation.aip.org/content/aapm/journal/medphys/43/2/10.1118/1.4939223'
Right1,Right2,Right3,